MaaT Pharma Awarded France Relance Government Grant to Accelerate Development in Immuno-Oncology and Support Manufacturing of Next Generation Microbiome Therapies
Summary
Initiated during the Summer of 2020, Plan France Relance was established to make strategic investments in critical sectors of French industry, including Health. The first relies on healthy donor donations (“native” products) and aims to restore the gut microbiota of patients with liquid tumors (notably leukemia). With its therapies, MaaT Pharma aims to synthetically replicate a responder microbiota, combining high richness and diversity with selected functional networks in each indication of interest to improve the response to immune checkpoint inhibitors. Supporting the development and expansion of our pipeline, we have built a powerful discovery and analysis platform, GutPrint®, to determine novel disease targets, evaluate drug candidates and identify biomarkers for microbiome-related conditions. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.